Bristol Myers’ iberdomide shows improvement in Phase 3 myeloma study

Bristol Myers (BMY) announced that the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an investigational cereblon E3 ligase modulator – CELMoD -, combined with standard therapies – daratumumab + dexamethasone – in patients with relapsed or refractory multiple myeloma, or RRMM, demonstrated a statistically significant improvement in minimal residual disease, or MRD, negativity rates, compared with the control arm, in a planned interim analysis of the MRD endpoint. In accordance with the trial design and based on the recommendation from the Data Monitoring Committee, the trial will continue without changes to evaluate the other dual-primary endpoint of progression-free survival, and the key secondary endpoint of overall survival and safety. The safety profile of iberdomide in combination with daratumumab and dexamethasone in this study is generally consistent with previous studies. The company plans to discuss these results with health authorities.